泰格醫藥(03347.HK)擬出資7000萬元參與投資合夥企業
格隆匯 3 月 29日丨泰格醫藥(03347.HK)公佈,公司投資平台杭州泰格股權投資合夥企業(有限合夥)擬以自有資金投資福清麒盛肆號投資合夥企業(有限合夥)(以下簡稱"合夥企業")。合夥企業的目標認繳出資總額為人民幣2億元,公司將作為該合夥企業的有限合夥人(LP)認繳出資人民幣7,000萬元。
此次投資主體為公司全資子公司杭州泰格股權投資合夥企業(有限合夥),其成立於2016年4月22日,系公司專業投資平台,由兩名合夥人共同發起設立,執行事務合夥人為上海泰格醫藥科技有限公司,有限合夥人為杭州泰格醫藥科技股份有限公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.